What Cypath does

Cypath is a French physician-owned medical group (SELAS) specializing in anatomical and cytological pathology, organized as a multi-site network of 15 laboratories across Auvergne-Rhône-Alpes, Bourgogne-Franche-Comté, Grand-Est, and Martinique. It serves a referral base of nearly 180 healthcare establishments and a long tail of specialist practices (gynecologists, dermatologists, surgeons, GPs, midwives), performing over 900,000 examinations annually with a workforce of 75 liberal-pathologist associates and roughly 390 cytotechnicians, technicians, secretaries, and couriers.

The group's service portfolio spans routine histopathology and cytology, comprehensive cervical cancer screening (liquid-based cytology, HPV typing, co-testing, AI-assisted reading via the GENIUS HOLOGIC system), and a somatic genetics platform covering NGS panels (Illumina NextSeq 550DX with Agilent capture, including 39-gene DNA and 61-gene RNA panels), real-time PCR companion diagnostics, FISH, and liquid biopsy. Sub-brands include Dermapath (a cross-site dermatopathology specialist network) and CYPATH-RB, a 2021-vintage wholly-owned research subsidiary with ISO 9001 and ISO 20387 certifications covering clinical research, AI tool development, and biological resource center operations.

Cypath is remunerated on a fee-for-service basis under France's CCAM V2 nomenclature, billed through national health insurance and supplementary insurers, with innovative genetic testing financed under the RIHN framework. Distribution is B2B-led through referring physicians and healthcare facility contracts, supplemented by a direct-to-patient result and payment portal for cervical screening. The group is physician-governed, with no pharmaceutical shareholders, and has pursued growth through site acquisitions (Besançon Pathologie in January 2022; Saint-Etienne integration in 2022), physician recruitment (11 new associates in 2025), and external research collaborations such as the ARCAGY-GINECO GREAT ovarian cancer study.

Name

Cypath

Legal name

CYPATH

Website

https://cypath.fr

Company type

Private

Founded year

1964

Operating status

Operating

Headcount range

251–500 employees

Short description

Cypath is a French physician-owned multi-site pathology group operating 15 laboratories that deliver anatomical, cytological, and molecular diagnostics to nearly 180 healthcare establishments and specialist referrers across four French regions, processing over 900,000 examinations annually.

Ownership category

akta.pro rank

Product category

Pathology Diagnostic Services

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Anatomic Pathology (Histopathology & Cytopathology) (HLAFAMAA)

akta.pro secondary industries

Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays) (HLAAALAI), Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy) (HLAAAMAB), Companion Diagnostics (CDx) Development & Commercialization (HLAAANAC), Pathology Reporting, Synoptic Templates & Cancer Registry Interfaces (HLACAMAJ)

Keywords

• Anatomical pathology services
• Cytology diagnostics
• Somatic genetics testing
• Cervical cancer screening
• Companion diagnostics

Headquarters

HQ city

Villeurbanne

HQ country

France

HQ region

Europe

Offices22 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Pathology Examination Services: Fee-for-service medical billing for anatomical and cytological pathology examinations including histological tests, cytological tests, and virological tests. Revenue is generated through national health insurance (Sécurité Sociale) and supplementary insurance (mutuelles) according to the Classification Commune des Actes Médicaux (CCAM V2).
2. Molecular Biology and Genetic Testing: Innovative genetic testing services (somatic genetics) financed through the innovative procedures reference (RIHN) framework, enabling patients to benefit from molecular tests not yet included in standard nomenclature.
3. Co-Testing Services: Combined cervical cancer screening combining liquid-based cytology and HPV testing, billed as integrated service with unified report.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Cypath is an independent French medical group providing anatomical and cytological pathology diagnostic services across 15 sites in France. The company offers histological examinations (biopsies, surgical resections), cytological examinations (cervical smears, fine needle aspirations), molecular biology and somatic genetics testing for companion diagnostics, dermatopathology, and AI-assisted cervical cancer screening. The group serves healthcare professionals who refer patient samples, with results delivered through secure messaging systems and online portals.

Product overview

CYPATH is a multi-site independent pathology group comprising 15 locations across Auvergne-Rhône-Alpes, Bourgogne-Franche-Comté, Grand-Est, and Martinique regions. The company operates as a unified medical cabinet offering anatomic and cytology pathology diagnostic services, organized around several integrated components: core diagnostic services (histopathology, cytology, immunohistochemistry), a somatic genetics platform for companion diagnostics (NGS, PCR, FISH), the Dermapath dermatopathology network, the CYPATH-RB research subsidiary, and specialized cervical cancer screening with AI-assisted reading. The portfolio also includes liquid biopsy services, digital pathology infrastructure, and a web-based molecular prescription portal. With 75 pathologists and nearly 400 collaborators, the group processes over 900,000 examinations annually.

Differentiator

Problem solved

Functional benefit

Brands

• Dermapath: A qualified network of dermatopathology specialists within the CYPATH group, spanning multiple sites, focused on improving analysis quality of cutaneous-mucosal samples and strengthening links with clinicians.
• e-PATH

Products and services

• Cypath Diagnostic Services Anatomic and cytology pathology diagnostic services including histological examinations (biopsies, surgical resections), cytological examinations (cervical smears, fine needle aspirations, effusions), and complementary techniques (immunohistochemistry, special stains). For healthcare professionals, hospitals, and clinics requiring pathological diagnosis.
• Somatic Genetics Platform Molecular biology platform for cancer genetic testing including real-time PCR, next-generation sequencing (NGS), and fluorescence in situ hybridization (FISH). Tests detect tumor mutations for targeted therapy decisions in lung, colon, skin, sarcoma, and breast cancers. For oncologists and healthcare professionals guiding personalized treatment.
• Cervical Cancer Screening Comprehensive cervical cancer screening including liquid-based cytology (ThinPrep), HPV testing (COBAS 6800 ROCHE), co-testing, and AI-assisted reading (GENIUS HOLOGIC). For gynecologists, midwives, and patients participating in cervical screening programs.
• Dermapath Network Qualified dermatopathology physician network within Cypath combining specialists from multiple sites for specialized skin pathology analysis. Includes collegial review of difficult cases, anatomo-clinical correlation meetings, and participation in national expert networks (CARADERM, GFELC). For dermatologists and clinicians requiring specialized skin pathology.
• CYPATH-RB Research Services Research subsidiary offering clinical research support, AI tool development, and biological resource center (CRB) services. For research institutions, pharmaceutical companies, and clinical study sponsors requiring annotated biological samples and pathology research support.
• Liquid Biopsy Service Liquid biopsy technique for detecting circulating tumor DNA genetic abnormalities in cancer patients. Enables non-invasive cancer monitoring and genetic profiling from blood samples. For oncologists and patients requiring cancer monitoring without invasive tissue biopsies.
• Web Prescription Platform (NetSIG) Online molecular biology prescription portal for healthcare professionals to order genetic tests and access results electronically. For oncologists, pathologists, and prescribing physicians ordering companion diagnostic tests.

Quantifiable outcome

• Nearly 330,000 cervical cancer screening dossiers processed in 2021
• +3 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability3 records

Feature8 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• ARCAGY-GINECOcoreStrategic or Co-development Partner · 3 March 2021Cypath participates in the GREAT study in collaboration with ARCAGY-GINECO's biological resource center. Since March 3, 2021, Cypath's molecular biology platform transmits tissue material and patient DNA to the biological resource center, along with BRCA1, BRCA2 and homologous recombination system gene mutation research results for ovarian cancer research.
• e-PATHcoreStrategic or Co-development Partnere-PATH is a company grouping 5 groups of liberal pathologists across France, created to anticipate evolutions in anatomical pathology. Cypath participates in this network for shared molecular biology platforms and collaborative development of somatic genetic testing services.
• HOLOGICcoreTechnology or IntegrationPartnership for cervical cancer screening technology including Thinprep liquid-based cytology automates and GENIUS AI-assisted screening system for preselection of cellular elements on cervical smear slides.
• Roche (COBAS 6800)coreTechnology or IntegrationPartnership for HPV oncogenic typing using COBAS 6800 ROCHE automates for fully automated molecular biology testing.
• IlluminacoreTechnology or IntegrationUse of Illumina NextSeq 550DX sequencer for next-generation sequencing applications in somatic genetics testing.
• AgilentcoreTechnology or IntegrationUse of Agilent capture panels for NGS applications including 39-gene solid tumor DNA panel, 61-gene solid tumor RNA panel, and homologous recombination gene panel.
• DERMAPATH NetworkcoreStrategic or Co-development PartnerInternal network of dermatopathology specialists within Cypath grouping physicians from different sites with specialized training in dermatopathology, organizing collegial review of difficult cases and participating in national expert networks.
• CARADERMminorStrategic or Co-development PartnerHospital network for rare skin cancer management supported by INCa, with Dermapath network physicians participating in case reviews and expert consultations.
• GFELC (Groupe Français d'Étude des Lymphomes Cutanés)minorStrategic or Co-development PartnerFrench study group for cutaneous lymphomas with Dermapath network participation in national review sessions.
• Société Française de Pathologie (SFP)minorOthersProfessional medical society for continuing education and professional development.
• Académie Internationale de Pathologie (AIP)minorOthersInternational professional society for pathology continuing education and knowledge sharing.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Others

• Caris Life Sciences: US-based molecular profiling and AI-driven pathology company. Comparable to Cypath's stated ambition around combining NGS, liquid biopsy, and AI; represents a potential international model for Cypath's CDx + AI roadmap.
• Foundation Medicine: Leading molecular profiling and CDx developer (Roche subsidiary). Cypath competes indirectly via NGS-based solid tumor panels and shares the same biopharma CDx partnership channel through e-PATH and ARCAGY-GINECO collaborations.
• Biocartis: Molecular diagnostics platform vendor focused on rapid oncology testing (Idylla). An enabling/adjacent player whose distributed PCR technology could complement Cypath's existing Roche/Illumina/Agilent stack for near-patient CDx workflows.

Direct peers

• Unilabs: European diagnostics leader offering anatomic pathology, cytology, and molecular diagnostics across multiple countries; directly overlaps Cypath's portfolio in France (including a Paris site referenced as "Unilabs Pathologie Paris" in Cypath's own office list). Comparable in cervical screening and CDx services.
• Cerba HealthCare: French-headquartered clinical laboratory and specialty diagnostics provider with strong anatomic pathology and companion diagnostic capabilities. Highly comparable in CDx co-development, NGS-based somatic genetics, and French hospital contract competition.
• Inovie: Major French independent medical biology and pathology group with multi-site presence. Directly competes for hospital and private-practice referrals across France with similar anatomic pathology and molecular services.
• Eurofins Genomics: European molecular diagnostics and genomics services provider with strong NGS and CDx capabilities. Comparable to Cypath's somatic genetics platform (NGS panels, PCR, FISH) and supports biopharma CDx programs.
• HalioDx (Veracyte): Specialized immune-oncology and tumor profiling diagnostics provider; comparable in CDx development and oncology molecular profiling work that Cypath pursues through its somatic genetics platform.

Broad incumbents

• Synlab: Europe's largest clinical laboratory services provider operating across dozens of countries; competes broadly in anatomic pathology, cytology, and molecular diagnostics. Much larger scale, broader geographic reach, and deeper commercial resources than Cypath.
• NeoGenomics: US-listed oncology-focused clinical laboratory with broad anatomic pathology, molecular, and CDx services. Comparable in CDx and precision oncology testing menu, though primarily US-focused.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cypath